Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hope for families: new drug trial targets autism irritability in kids

NCT ID NCT07284745

Not yet recruiting Symptom relief Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 4 times

Summary

This study tests whether a new medication, KarXT + KarX-EC, can reduce irritability in children and teens (ages 5 to 17) with autism. About 176 participants will receive either the drug or a placebo. The main goal is to see if the drug improves irritability scores after 8 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autism spectrum disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IRRITABILITY ASSOCIATED WITH AUTISM SPECTRUM DISORDER

Contacts and locations

Locations

  • Local Institution - 0007

    Brisbane, Queensland, 4101, Australia

  • Local Institution - 0010

    Westmead, New South Wales, 2145, Australia

  • Local Institution - 0031

    Anaheim, California, 92805, United States

  • Local Institution - 0036

    Dothan, Alabama, 36303, United States

  • Local Institution - 0041

    Dallas, Texas, 75243, United States

  • Local Institution - 0045

    Melbourne, Victoria, 3052, Australia

  • Local Institution - 0074

    Bountiful, Utah, 84010, United States

  • Local Institution - 0099

    Gainesville, Florida, 32607, United States

  • Local Institution - 0110

    Las Vegas, Nevada, 89128, United States

  • Local Institution - 0135

    Kingston, Ontario, K7L4X3, Canada

  • Local Institution - 0136

    Edmonton, Alberta, T6G 1Z1, Canada

  • Local Institution - 0155

    Peachtree Corners, Georgia, 30071, United States

  • Local Institution - 0160

    Bloomfield Hills, Michigan, 48302, United States

  • Local Institution - 0181

    San Rafael, California, 94903, United States

  • Local Institution - 0185

    Spring, Texas, 77381, United States

  • Local Institution - 0187

    Montreal, Quebec, H3T 1C5, Canada

  • Local Institution - 0205

    Toronto, Ontario, M4G 1R8, Canada

  • Local Institution - 0220

    Detroit, Michigan, 48203, United States

  • Local Institution - 0233

    Redlands, California, 92373, United States

  • Local Institution - 0236

    Phoenix, Arizona, 85006, United States

  • Local Institution - 0242

    Louisville, Kentucky, 40202, United States

  • Local Institution - 0246

    Staten Island, New York, 10312, United States

  • Local Institution - 0247

    West Chester, Ohio, 45069, United States

  • Local Institution - 0252

    Colorado Springs, Colorado, 80910, United States

  • Local Institution - 0257

    Glendale, California, 91203, United States

  • Local Institution - 0260

    Richmond, Virginia, 23220, United States

  • Local Institution - 0263

    The Bronx, New York, 10461, United States

  • Local Institution - 0264

    Boca Raton, Florida, 33428, United States

  • Local Institution - 0266

    Chicago, Illinois, 60622, United States

  • Local Institution - 0269

    Danville, Pennsylvania, 17821, United States

  • Local Institution - 0271

    Provo, Utah, 84604, United States

  • Local Institution - 0273

    Plano, Texas, 75093, United States

  • Local Institution - 0278

    Gainesville, Florida, 32607, United States

  • Local Institution - 0286

    Melbourne, Victoria, 3168, Australia

  • Local Institution - 0289

    Airdrie, Alberta, T4A 0K9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.